Device Trial Radar · NCT07550361
Validation of Non-Invasive Intracranial Pressure Estimation Using CPMX3 in the Periorbital Vein: A Feasibility Study in Pediatric Patients
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 22, 2025
Primary completion
Apr 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Compremium AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 8 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Intracranial pressure (ICP) monitoring is indicated in a wide range of neurological diseases. The combination of a linear ultrasound array with an integrated pressure sensor into a single handheld probe (ICP Probe) enables the user to precisely and non-invasively estimate blood pressure in a superficial vein overlying a hard structure. The periorbital vein located on the forehead above the eye is an interesting target since it is an emissary vein, directly connected through valveless vessels to the intracranial venous system. Its pressure might thus reflect intracranial pressure if it can be measured before being equalized by redistribution across the whole facial venous network. The usage of a pneumatic mask able to transiently occlude the site of measurement from the superficial venous network might therefore enable to correlate the venous occlusion pressure (VOP) of the periorbital vein to ICP. To confirm the hypothesis, the current clinical trial will compare measurements made with the CPMX3 system with invasively obtained ICP measures.
Conditions
- Intracranial Pressure
Interventions
CPMX3 measurementDevice
CPMX3 ICP measurement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of venous occlusion pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP in pediatric patients.Time frame: Up to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's National Hospital
Washington D.C., District of Columbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.